In conclusion, our findings reveal novel biological insight into how the SHH pathway regulates the migration of ovarian cancer cells and provides strong evidence that combined treatment with the SHH pathway inhibitor and autophagy inhibitor might be an effective therapeutic option in ovarian cancer therapy. This evidence concerns the gene SHH and ovarian carcinoma.